Dr.
About Lixte Biotechnology Holdings, Inc.:
Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.
About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):
NINDS (www.ninds.nih.gov) is a component of the National Institutes of Health (NIH), and is the nation's primary supporter of biomedical research on the brain and nervous system.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Forward-Looking Statements:
This announcement contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, and Section 21E of the
Securities Exchange Act of 1934. For example, statements regarding the
Company's financial position, business strategy and other plans and objectives
for future operations, and assumptions and predictions about future product
demand, supply, manufacturing, costs, marketing and pricing factors are all
forward-looking statements. These statements are generally accompanied by
words such as "intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could," "would,"
"should," "expect" or the negative of such terms or other comparable
terminology. The Company believes that the assumptions and expectations
reflected in such forward-looking statements are reasonable, based on
information available to it on the date hereof, but the Company cannot provide
assurances that these assumptions and expectations will prove to have been
correct or that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements are
inherently subject to known and unknown risks and uncertainties. Actual
results or experience may differ materially from those expected or anticipated
in the forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar businesses,
and market and general economic factors. This discussion should be read in
conjunction with the condensed consolidated financial statements and notes
thereto included on Form 10-QSB for the quarter ending
Please see our Website: www.Lixte.com For Investor Information, please contact: Frank Benedetto Mirador Consulting, Inc. 561-989-3600
SOURCE Lixte Biotechnology Holdings, Inc.